Experimental Vaccine Shows Promise Against Brain Cancer
An experimental vaccine, SurVaxM, extended survival in younger glioblastoma patients, though it narrowly missed its overall trial goal.
Tag
5 articles
An experimental vaccine, SurVaxM, extended survival in younger glioblastoma patients, though it narrowly missed its overall trial goal.
Moderna shares surged 177% after its personalized mRNA cancer vaccine met Phase 3 endpoints in melanoma, marking a historic milestone for cancer treatment.
A Johns Hopkins vaccine targeting KRAS mutations safely triggered immune responses in 90% of participants, a breakthrough in pancreatic cancer prevention.
Moderna and Merck's mRNA vaccine reduced melanoma recurrence risk by 49% over five years, offering new hope for advanced skin cancer patients.
A personalized mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence risk by 49% over five years, according to new clinical trial data.